drugset / Trial / NCT07597941
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
NaSingle-groupOpen-labelPrevention
Summary
This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 50 mg | — |
| Subject | APG-2575 | Small molecule | 100 mg | — |